Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non-critical COVID-19 pneumonia: A double-blind randomized, placebo-controlled clinical trial.
Faranak SedighiMehran ZarghamiFatemeh Alizadeh ArimiMahmood MoosazadehShahram AlaRoya GhasemianHossein MehravaranForouzan ElyasiPublished in: Neuropsychopharmacology reports (2023)
Fluoxetine resulted in a faster reduction of patients' inflammation without association with depression and anxiety.
Keyphrases
- double blind
- placebo controlled
- clinical trial
- phase ii
- end stage renal disease
- phase iii
- open label
- coronavirus disease
- ejection fraction
- sars cov
- chronic kidney disease
- newly diagnosed
- study protocol
- oxidative stress
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- combination therapy
- patient reported
- acute respiratory distress syndrome